Hence, tumor genotyping is not required if these two methylation biomarkers are used for ctDNA detection, and testing for methylated BCAT1/IKZF1 ctDNA is unlikely to be confounded by tumor heterogeneity or clonal drift following adjuvant therapy. This evidence concerns the gene BCAT1 and neoplasm.